Terns Pharmaceuticals (TERN) Operating Income (2020 - 2022)
Historic Operating Income for Terns Pharmaceuticals (TERN) over the last 3 years, with Q4 2022 value amounting to -$16.8 million.
- Terns Pharmaceuticals' Operating Income fell 2125.67% to -$16.8 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$62.0 million, marking a year-over-year decrease of 2440.63%. This contributed to the annual value of -$101.9 million for FY2024, which is 66.99% up from last year.
- Latest data reveals that Terns Pharmaceuticals reported Operating Income of -$16.8 million as of Q4 2022, which was down 2125.67% from -$17.3 million recorded in Q3 2022.
- In the past 5 years, Terns Pharmaceuticals' Operating Income registered a high of -$8.7 million during Q3 2020, and its lowest value of -$17.3 million during Q3 2022.
- Moreover, its 3-year median value for Operating Income was -$12.6 million (2021), whereas its average is -$12.4 million.
- Its Operating Income has fluctuated over the past 5 years, first crashed by 5828.01% in 2021, then plummeted by 397.86% in 2022.
- Over the past 3 years, Terns Pharmaceuticals' Operating Income (Quarter) stood at -$8.8 million in 2020, then plummeted by 58.28% to -$13.9 million in 2021, then dropped by 21.26% to -$16.8 million in 2022.
- Its Operating Income was -$16.8 million in Q4 2022, compared to -$17.3 million in Q3 2022 and -$14.1 million in Q2 2022.